• Background/Aim: This study analyzed the outcomes of docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy and DCF plus concurrent radiotherapy (DCF-RT), both followed by conversion surgery, if possible, in patients with cT4b esophageal cancer. (iiarjournals.org)
  • Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. (helsedirektoratet.no)
  • Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (helsedirektoratet.no)
  • Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. (springermedizin.at)
  • A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. (ichgcp.net)
  • Docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy can cause severe adverse events, including neutropenia and febrile neutropenia. (biomedcentral.com)
  • Women of child-bearing potential (WOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for the duration of the study treatment and up to 2 months after the last dose of PRGN-2009 and an effective method of contraception (barrier, hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for 14 months after the last dose of cisplatin/docetaxel. (who.int)
  • Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. (nature.com)
  • The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival in patients with advanced biliary tract cancer, accord. (ascopost.com)
  • In patients with unresectable/metastatic HCC at diagnosis, to determine whether the addition of gemcitabine and oxaliplatin (GEMOX + sorafenib) to a cisplatin, doxorubicin and sorafenib backbone improves chemotherapy response, resectability and survival. (ucsf.edu)
  • Perioperative durvalumab with gemcitabine/cisplatin in patients with resectable MIBC resulted in high EFS and OS at 2 years. (guoncologynow.com)
  • Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma. (cancercentrum.se)
  • This is a review of morbidity and mortality for first 51 MIE procedures for locally advanced esophageal cancer, that were resectable, on post neoadjuvant computerized tomography (CT) of chest and abdomen. (hindawi.com)
  • This trial confirms that preoperative chemoradiation for resectable esophageal cancer is safe and, compared with surgery alone, is associated with pathological complete responses, higher rates of R0 resection, and prolonged survival. (medscape.com)
  • Current options for resectable esophageal cancer include preoperative cisplatin-based radiotherapy and preoperative or perioperative chemotherapy alone (either 5-fluorouracil/cisplatin, as in the UK Medical Research Council study, [ 1 ] or epirubicin, cisplatin and fluorouracil, as in the MAGIC study [ 2 ] ). (medscape.com)
  • The FFCD 9102 trial randomized 444 patients with resectable esophageal cancer (majority squamous histology) to induction CRT consisting of either 46 Gy in 23 fractions with concurrent cisplatin and 5-FU or split course 30 Gy in 10 fractions RT given over 4 weeks (5 days on, 10 days off, 5 days on). (appliedradiationoncology.com)
  • Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. (springermedizin.at)
  • To compare in a randomized fashion, EFS in patients with intermediate risk HB treated with 6 cycles of cisplatin/5-fluorouracil/vincristine/doxorubicin (C5VD) chemotherapy versus 6 cycles of interval compressed cisplatin monotherapy (100 mg/m 2 /dose). (ucsf.edu)
  • 8-13 Walsh et al evaluated outcomes of esophageal adenocarcinoma (AC) patients treated with 40 Gy in 15 fractions of RT combined with cisplatin and 5-fluorouracil (5-FU) chemotherapy followed by surgical resection compared with surgical resection alone. (appliedradiationoncology.com)
  • She was treated with pembrolizumab, cisplatin, and 5-fluorouracil. (springeropen.com)
  • The combination of cisplatin and 5-fluorouracil (FP) has been considered the standard treatment for chemotherapy in cases of ESCC with distant metastasis [ 4 ]. (springeropen.com)
  • Neoadjuvant oncological treatment for gastro-oesophageal junction cancer previously consisted of the intravenous administration of epirubicin, cisplatin and fluorouracil (ECF) or epirubicin, cisplatin and capecitabine (ECX) combination (Group I). In the course of the new protocol (FLOT-, F: 5-FU, L: leucovorin, O: oxaliplatin, T: docetaxel), patients were included with resectable gastro-oesophageal junction cancer who had a clinical-stage cT2 or higher nodal positive cN+ disease (Group II). (akjournals.com)
  • Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (cincinnatichildrens.org)
  • and 69.3% vs 74.9% received cisplatin and 21.8% vs 18.4% received carboplatin as part of doublet chemotherapy. (ascopost.com)
  • The investigators randomly assigned patients with resectable cancers to undergo surgery alone or receive weekly carboplatin (area under the curve, 2) and paclitaxel (50 mg/m 2 ) for 5 weeks and concurrent radiotherapy, followed by surgery. (medscape.com)
  • Cisplatin and Carboplatin are drug of choice in HNC treatment. (waocp.com)
  • Systemic agents commonly prescribed in head and neck cancer treatment includes Cisplatin, Cetuximab and Carboplatin. (waocp.com)
  • However, if patient develops side effects because of cisplatin or patient overall health condition is not well at the start of treatment because of age factors and other co-morbid patients are prescribed cetuximab (targeted therapy) and last option is carboplatin (slightly less effective but cost-effective). (waocp.com)
  • that is, for a dose that usually requires a particular dose of cisplatin, four times more carboplatin is needed to achieve the same effectiveness" (p.193). (waocp.com)
  • Several analogs of cisplatin have been synthesized such as carboplatin and oxiplatin. (waocp.com)
  • Chemoradiotherapy Combined with Nab-Paclitaxel plus Cisplatin in Patients with Locally Advanced Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Study. (medline.ch)
  • This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). (msdoncologyclinicaltrials.com)
  • This study therefore offers a new option of weekly chemotherapy with concurrent radiotherapy for patients with resectable esophageal (but not gastric) cancers. (medscape.com)
  • The management of resectable rectal cancer continues to be guided by clinical trials and advances in technique. (biomedcentral.com)
  • Pancreatic tumors that are considered to be borderline resectable may warrant neoadjuvant therapy to shrink the tumor for surgical intervention, with the goal of cure. (jhoponline.com)
  • 5 According to a meta-analysis review of clinical trials examining the use of neoadjuvant FOLFIRINOX therapy for patients with pancreatic cancer, an estimated 68% of patients with borderline resectable disease will successfully undergo resection after 4 to 9 cycles of neoadjuvant FOLFIRINOX, with each cycle administered every 14 days. (jhoponline.com)
  • Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. (biomedcentral.com)
  • The study investigates the effect of neoadjuvant chemoradiation in locally resectable or probably resectable cancer of the pancreatic head without distant metastasis on median overall survival time compared to primary surgery. (biomedcentral.com)
  • The 5-year overall survival of patients with pancreatic cancer is approximately 5%, with potentially resectable disease representing the curable minority. (cancernetwork.com)
  • Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). (springermedizin.at)
  • Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial). (springermedizin.at)
  • To determine the event-free survival (EFS) in patients with HB whose tumor is completely resected at diagnosis and either receive no adjuvant chemotherapy (completely resected well differentiated fetal [WDF] histology HB) or 2 cycles of standard dose cisplatin monotherapy (completely resected non-well differentiated fetal histology HB - 100 mg/m 2 /cycle given 3 weeks apart). (ucsf.edu)
  • Patients with small tumors (usually asymptomatic) that appear resectable usually undergo thoracotomy and attempted complete resection followed by chemotherapy. (wikipedia.org)
  • Locally advance, un-resectable tumors are treated with systemic therapies. (waocp.com)
  • Hence, systemic therapies are used to treat tumors that are un-resectable, locally advance and for the purpose of organ preservation [6]. (waocp.com)
  • Cisplatin is used in variety of tumors including cancers of the ovaries, testes, and solid tumors of the head and neck. (waocp.com)
  • In patients whose tumors are deemed unresectable after 2 cycles of cisplatin monotherapy, to determine the proportion of tumors rendered completely resectable by an additional 2 or 4 cycles of chemotherapy. (ucsf.edu)
  • A phase II trial associating the reference chemotherapy (pemetrexed plus cisplatin) with bevacizumab is needed to ensure that no specific toxicity is induced by this association, and that this triplet have interesting activity. (knowcancer.com)
  • This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma . (ucsf.edu)
  • it involves dissection of the parietal pleura and division of the pulmonary vessels, as well as en bloc resection of the lung, pleura, pericardium, and diaphragm, followed by reconstruction. (medscape.com)
  • He underwent surgical resection, 6 weeks of craniospinal radiation (2,340 cGy to the spine and whole brain with a 3,240 cGy boost to the posterior fossa), and eight cycles of chemotherapy with CCNU (lomustine), vincristine, and cisplatin. (cancernetwork.com)
  • The study population will include male and female patients over the age of 18 with muscle invasive urothelial carcinoma of the bladder (MIBC) who are not suitable for cisplatin-based chemotherapy or refuse chemotherapy, but are fit to undergo surgical resection of their cancer by cystectomy. (uchicagomedicine.org)
  • Patients (pts) had histologically verified, previously untreated, measurable or evaluable non-resectable NSCLC, without brain metastases and with normal organ functions. (coek.info)
  • As reported in The New England Journal of Medicine by Forde et al, the phase III CheckMate 816 trial has shown improved pathologic complete response rate and event-free survival with the addition of nivolumab to platinum-based chemotherapy in the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC). (ascopost.com)
  • The trial supported the March 2022 approval of nivolumab combined with platinum-doublet chemotherapy for resectable NSCLC in the neoadjuvant setting. (ascopost.com)
  • The investigators concluded: "In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone. (ascopost.com)
  • Patients with treatment-naive resectable non-small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival a. (ascopost.com)
  • Sorensen, H. Larsen, H.H. Hansen Department of Oncology, Finsen Center, The National Unzversity Hospital, DK-2100 Copenhagen, Denmark There is currently no standard chemotherapy regimen for treatment of non-resectable NSCLC. (coek.info)
  • From the abstract: 'Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small-cell lung cancer (NSCLC). (cdc.gov)
  • DK completed treatment in October 2001 after receiving a cumulative cisplatin dose of 450 mg/m2. (cancernetwork.com)
  • Cisplatin is a drug of choice, given either in a three weekly or weekly dose (in case of side effects develop with three weekly doses). (waocp.com)
  • 9 Similarly, the European Organization for Research and Treatment of Cancer (EORTC) trial 8 randomized SCC patients to surgery alone or neoadjuvant CRT consisting of two 1-week courses of RT, separated by a 2-week break, to a total dose of 37 Gy in 10 fractions with concurrent cisplatin. (appliedradiationoncology.com)
  • All patients undergoing MIE at Shaukat khanum Memorial Cancer Hospital, for resectable esophageal cancers between January 2011 and May 2013, were reviewed. (hindawi.com)
  • This is phase II clinical trial design randomizing patients who are cisplatin-ineligible or chemotherapy-refusing with MIBC (stages T2-T4, N0-N2, M0) to one of two treatment arms: Arm A - Nivolumab in combination with Urelumab or Arm B - Nivolumab monotherapy. (uchicagomedicine.org)
  • Group C) V. To determine the EFS in patients with HCC whose tumor is completely resected at diagnosis who receive no adjuvant chemotherapy (completely resected HCC arising in the context of underlying liver disease) or 4 cycles of cisplatin/doxorubicin (PLADO) (completely resected de novo HCC). (ucsf.edu)
  • To improve the EFS of patients with high risk HB by treating them with interval compressed cisplatin and doxorubicin based induction regimen followed by response-adapted consolidation therapy. (ucsf.edu)
  • Since 2001, select patients with mesothelioma at Prince Margaret Hospital and Toronto General Hospital in Toronto, Canada, have been treated with an aggressive regimen that begins with 3 cycles of cisplatin-based chemotherapy followed by staging to see if they were still possibly resectable. (cancergrace.org)
  • 4 Unfortunately, most patients are present with advanced (non-resectable or metastatic) disease and their survival is ≤3 months, with best supportive care alone. (nature.com)
  • For all stages, 5 year overall survival rate is 6% form en and 3% for women[ 1 ]. (biomedcentral.com)
  • AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. (cancercentrum.se)
  • Patients with resectable disease then underwent minimally invasive esophagectomy (MIE). (hindawi.com)
  • In the open-label international trial, 358 patients with stage IB to IIIA resectable disease were randomly assigned between March 2017 and November 2019 to receive neoadjuvant treatment with nivolumab at 360 mg plus platinum-doublet chemotherapy (n = 179) or platinum-doublet chemotherapy alone (n = 179) every 3 weeks for three cycles before definitive surgery. (ascopost.com)
  • Patients with resectable clinical node positive disease within the true pelvis are eligible. (uchicagomedicine.org)
  • 40 mg/m 2 on day 1 every 4 weeks (in combination with cisplatin, etoposide, and mitotane) (Fassnacht 2012) or 20 mg/m 2 on days 1 and 8 every 4 weeks (in combination with cisplatin, etoposide, and mitotane) until disease progression or unacceptable toxicity up to a maximum of 6 cycles (Berruti 2005). (medilib.ir)
  • Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. (cdc.gov)
  • In patients who are resected after 2 cycles of cisplatin monotherapy, to compare EFS following a randomized comparison of 2 versus 4 post-operative cycles of cisplatin monotherapy. (ucsf.edu)
  • After treatment, conversion surgery (CS) was performed for the residual tumor in resectable cases. (iiarjournals.org)
  • It is the most ototoxic drug used clinically, and hearing loss is a well-recognized toxicity of cisplatin therapy. (cancernetwork.com)
  • Further therapeutic advances and prospective trials are needed to better define the optimal role of adjuvant and neoadjuvant treatment in patients with resectable pancreatic cancer. (cancernetwork.com)
  • The reported incidence of hearing loss varies with differences in treatment protocols and patient variables, but hearing loss generally occurs in 20% to 70% of cisplatin recipients. (cancernetwork.com)
  • This study aimed to investigate cisplatin (DDP)-susceptibility regulated by expression of the miRNAs and underlying pathways in GBC. (oncotarget.com)
  • In this article, we review the data surrounding the use of chemotherapy (CT) and chemoradiotherapy (CRT) in patients with resectable pancreatic cancer. (cancernetwork.com)